首页> 外文期刊>Seminars in Oncology >Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
【24h】

Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

机译:Waldenstrom巨球蛋白血症的统一反应标准:第二届Waldenstrom巨球蛋白血症国际研讨会共识小组的建议。

获取原文
获取原文并翻译 | 示例
           

摘要

Waldenstrom's macroglobulinemia (WM) is a malignant disorder of lymphoplasmacytic cells that produce a monoclonal immunoglobulin M (IgM). Since the original description by Jan Waldenstrom of three patients with symptoms of hyperviscosity due to circulating monoclonal IgM, the definition of WM has been controversial. Standardized criteria for diagnosis have now been proposed, including the presence of any IgM monoclonal protein and marrow and/or nodal lymphoplasmacytic cells. Although previous response criteria have generally incorporated parameters for monoclonal protein reduction and/or improvement of marrowodal involvement, specific and uniform response criteria are needed to facilitate comparisons of response, remission duration, progression-free survival, and overall survival in clinical trials similar to those previously established for other diseases such as chronic lymphocytic leukemia, lymphoma, and myeloma. This is of particular importance as new agents are developed and evaluated. This presentation represents consensus recommendations for uniform response criteria for use in assessing responses to treatment for patients with WM, which were prepared in conjunction with the Second International Workshop held in Athens, Greece during September 2002. Semin Oncol 30:127-131.
机译:Waldenstrom的巨球蛋白血症(WM)是淋巴浆细胞的恶性疾病,可产生单克隆免疫球蛋白M(IgM)。自Jan Waldenstrom最初描述三名因循环单克隆IgM引起高粘度症状的患者以来,WM的定义一直存在争议。现在已经提出了诊断的标准化标准,包括是否存在任何IgM单克隆蛋白以及骨髓和/或淋巴结浆细胞。尽管以前的反应标准通常都包含用于减少单克隆蛋白和/或改善骨髓/淋巴结侵袭的参数,但仍需要特定且统一的反应标准以促进在临床试验中比较反应,缓解时间,无进展生存期和总生存期。以前针对其他疾病(例如慢性淋巴细胞性白血病,淋巴瘤和骨髓瘤)建立的那些。随着开发和评估新代理,这一点尤为重要。此演示文稿代表了用于评估WM患者对治疗的反应的统一反应标准的共识性建议,该标准是与2002年9月在希腊雅典举行的第二届国际研讨会共同制定的。Semin Oncol 30:127-131。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号